MonTa Biosciences is a Clinical Stage Biotech Company with a vision to develop better cancer treatment to patients by utilizing the immune system to recognize and kill tumor cells, and ultimately build up an immune memory response that will protect the patient from metastatic disease. Our lead candidate MBS8 has completed dose escalation studies in our phase I clinical trial with treatment of more than 80 patients at clinical sites in Denmark, Belgium and Spain.
MBS8 is a novel Lipid Nano Particle formulation with several unique selling points:
- Due to the Lipid Nano Particle (LNP) we have increased the Therapeutic Index by more than 20 fold
- MBS8 show more than 5 fold better anti tumor activity versus benchmark compound R848
- Immune stimulating LNPs are engineered to reduce systemic cytokine production with a favourable safety profile
- Administration by IV infusion is a major advantage for doctors and patients to minimize complications
- MBS8 is an LNP incorporating a small molecule TLR7 NCE agonist
- MBS8 show superior anti-tumor activity in preclinical models compared to many approved treatments
- Synergy with Immune Checkpoint Inhibitors, radiotherapy and chemotherapy with complete remission in preclinical models